SpliceBio
Spain - BarcelonaBiotechnology
Focus: SpliceBio is a Barcelona-based biotechnology company founded in 2024, specializing in intein technologies for gene therapy applications in oncology. The company is currently in early-stage development with minimal disclosed commercial infrastructure.
Profile data last refreshed 2h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Total Funding
$200M
Open Jobs
3+3 this month
Stable — net +3 jobs in 30d
3 added, 0 removed. Backfill posture.
Should You Work at SpliceBio?
AI assessmentSpliceBio is a high-risk, high-upside early-stage bet suitable only for career-stage scientists/operators comfortable with pre-clinical uncertainty and equity-heavy compensation in exchange for platform-building leverage.
Why Work Here
- Ground-floor opportunity at a newly founded (2024) biotech with a differentiated intein-based gene therapy platform in high-value oncology segment
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for SpliceBio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.